Thursday, Sept. 5, 2019
7 – 8 a.m.
Registration and Breakfast
Opening RemarksFranco Marincola, MD – Refuge Biotechnologies
Session I: State of the Field of Adoptive Cellular Therapy
8:05 – 9:35 a.m.
Alessandra Cesano, MD, PhD – ESSA Pharma Inc.Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
IntroductionAlessandra Cesano, MD, PhD – ESSA Pharma Inc.Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
T cells Recognizing Antigen Through Native or Chimeric ReceptorsHelen E. Heslop, MD – Baylor College of Medicine
Session II: External Circumstantial Factors
9:50 – 11:40 a.m.
Alessandra Cesano, MD, PhD – ESSA Pharma Inc.Christine Spencer, PhD – Parker Institute for Cancer Immunotherapy
CAR T cell Product Heterogeneity and Response to TreatmentJ. Joseph Melenhorst, PhD – University of Pennsylvania
Effects of Co-Morbidities and Concomitant Medications on Immunotherapy Efficacy and SafetyMichael N. Liebman, PhD – IPQ Analytics, LLC
Learning to Harness Cancer-Curing Poop as a Group: Collaborative Microbiome Research and Beyond at the Parker Institute for Cancer ImmunotherapyChristine Spencer, PhD – Parker Institute for Cancer Immunotherapy
Microbiome: Methods and New Technologies for Sample Collection and Assay StandardizationTessa Andermann, MD – Stanford University
Session III: Emerging Ideas and New Concepts
11:55 a.m. – 12:55 p.m.
Francesco M. Marincola, MD – Refuge Biotechnologies, Inc.Kyung-Ho Roh, PhD – University of Alabama in Huntsville
Detection and Activation of CAR-T Cells Using Standardized ModelsKyung-Ho Roh, PhD – University of Alabama in Huntsville
Conditional Regulation of CAR TStanley Qi, PhD – Stanford University
T cell ReprogrammingLuca Gattinoni, MD – National Cancer Institute
Session IV: Improving Risk and Benefit Profile of Adoptive Cellular Therapy
2 – 5 p.m.
Prasad S. Adusumilli, MD, FACS, FCCP – Memorial Sloan Kettering Cancer CenterDavid M. Barrett, MD, PhD – Children’s Hospital of Philadelphia
Understanding the Biology of CAR T ResistanceNathan Singh, MD – Washington University
Optimizing Synthetic Receptors to Prevent Relapse after Genetically Modified T Cell Therapy for LeukemiaTerry Fry, MD – Children’s Hospital Colorado
Beyond CAR T 2.0: Strategy to Reduce Toxicity – Safety Switches and Synthetic BiologyJulien Valton, PhD – Cellectis, Inc.
Beyond CAR T 2.0: Off the Shelf CAR TChristopher Haqq, MD, PhD – Atara Biotherapeutics
Beyond CAR T: NKT cell Platform for Adoptive cell TherapyLenoid Metelitsa, MD, PhD – Baylor College of Medicine
Manufacturing and Analytics in CAR T cell Technology: CAR T cell Product Characterization and FunctionXiuyan Wang, PhD – Memorial Sloan Kettering Cancer Center
Impact of the Tumor Microenvironment for CAR-T cell Therapy EfficacyJérôme Galon, PhD – INSERM, Sorbonne Universites Paris
Friday, Sept. 6, 2019
Session I: Adoptive Cellular-Specific Clinical Development and Regulatory Challenges
8:05 – 8:45 a.m.
Rayne Helen Rouce, MD – Baylor College of MedicineJohn M. Rossi, MS – Kite, A Gilead Company
Institution Readiness for Operationalizing CAR T cell Trials: Regulatory and Logistic ChallengesElizabeth J. Shpall, MD – The University of Texas MD Anderson Cancer Center
Regulatory Considerations for CAR T Cell Clinical StudiesAndrew Harmon, PhD – U.S. Food and Drug Administration
Session II: Real World Implementation and Scalability Challenges
9:05 – 10:05 a.m.
Marco L. Davila, MD, PhD – H. Lee Moffitt Cancer CenterAdrian P. Gee, PhD, MIBiol – Baylor College of Medicine
Process Optimization of Antigen Specific T cells for Clinical ApplicationsJuan F. Vera, MD – Baylor College of Medicine, Marker Therapeutics, AlloVir
Affordable CARs: Challenges to AccessibilityStephanie Farnia – Blue Cross Blue Shield
Working Group Breakouts
10:30 a.m. – 1:00 p.m.
Working Group 1:
Improving Benefit Profile of Adoptive Cellular Therapy
May Daher, MD – The University of Texas MD Anderson Cancer Center
Improving Risk Profile of Adoptive Cellular Therapy
Prasad S. Adusumilli, MD, FACS, FCCP – Memorial Sloan Kettering Cancer Center
Clinical, Regulatory, Implementation and Scalability Challenges of Adoptive Cellular Therapy
John M. Rossi, MS – Kite Pharma
Working Group Presentations
1:45 – 3:30 p.m.
Working Group 1: Improving Benefit Profile of Adoptive Cellular TherapyMay Daher, MD – The University of Texas MD Anderson Cancer Center
Working Group 2: Improving Risk Profile of Adoptive Cellular TherapyPrasad S. Adusumilli, MD, FACS, FCCP – Memorial Sloan Kettering Cancer Center
Working Group 3: Clinical, Regulatory, Implementation and Scalability Challenges of Adoptive Cellular TherapyJohn M. Rossi, MS – Kite Pharma
Schedule is subject to change.
This program has been supported, in part, by grants from Celgene Corporation, Kite, A Gilead Company, NanoString Technologies, Inc., Pfizer, Inc., and Refuge Biotechnologies.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com